Tiziana Reports Positive Longer-Term Data for Foralumab in MS Expanded Access Program
TLSA sits 20% above its 52-week low of $1.14.
Summary
Tiziana Life Sciences reported updated positive clinical data for its intranasal foralumab in MS, showing encouraging trends in disability stabilization and fatigue improvement in an Expanded Access Program.
Key Events · Product Development and Regulatory · TLSA
-
Updated Clinical Data for Foralumab
Intranasal foralumab showed encouraging trends in stabilizing disability (EDSS) and improving fatigue (MFIS) in 14 patients with non-active Secondary Progressive Multiple Sclerosis over extended treatment durations.
-
Favorable Safety Profile
The drug continued to be extremely well tolerated with no new safety signals identified, supporting its long-term use.
-
Data Limitations Noted
The results are from a small sample size and are not statistically significant, representing trend analysis only.
-
Context of Financial Health
This positive clinical update follows a recent 'going concern' warning in the company's 20-F filing, making any positive development for its lead candidate particularly important for future financing prospects.
Analysis · TLSA · Life Sciences
Tiziana Life Sciences announced updated clinical data from its Expanded Access Program for intranasal foralumab in non-active Secondary Progressive Multiple Sclerosis. The data, while from a small sample and not statistically significant, showed encouraging trends in stabilizing disability and improving fatigue over extended treatment durations, alongside a favorable safety profile. This positive clinical update provides further support for the drug's potential, which is crucial for the company given its recent 'going concern' warning.
At the time of this filing, TLSA was trading at $1.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $160.5M. The 52-week trading range was $1.14 to $2.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.